Lunai Bioworks Return on Equity

Lunai Bioworks (LNAI) currently reports a ROE of 39.47%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore Lunai Bioworks's ROE history and peer comparisons.

Lunai Bioworks's ROE of 39.47% is higher than the Healthcare sector average of 13.26%. That is roughly 197.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lunai Bioworks's current 39.47% should be judged against Healthcare norms (sector average: 13.26%) and against LNAI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 39.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Lunai Bioworks, and consider following LNAI for alerts when major investors trade the stock.

Lunai Bioworks is classified in the Healthcare sector. On ROE, it currently shows 39.47% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LNAI with unrelated industries.